Inactive Instrument

Acer Therapeutics Inc.

Equities

ACER

US00444P1084

Biotechnology & Medical Research

Acer Therapeutics Inc. Announces Resignation of William T. Andrews as Chief Medical Officer, Effective July 8, 2020

June 24, 2020 at 02:03 am IST

On June 19, 2020, William T. Andrews, M.D., FACP, notified Acer Therapeutics Inc. (the Company") of his intention to resign from his position as Chief Medical Officer of the Company, effective as of July 8, 2020.

Latest news about Acer Therapeutics Inc.

Acer Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	21/11	CI
Chris Schelling Ceases to Be Chief Executive Officer of Acer Therapeutics Inc	21/11	CI
Harry S. Palmin Ceases to Be Chief Financial Officer of Acer Therapeutics Inc	21/11	CI
Acer Therapeutics Inc. Announces Executive Changes	21/11	CI
Zevra Therapeutics Completes Acer Acquisition	20/11	MT
Zevra Therapeutics, Inc. completed the acquisition of Acer Therapeutics Inc. from funds affiliated with TVM Capital Life Science and others.	17/11	CI
Acer Therapeutics Inc.(OTCPK:ACER) dropped from S&P TMI Index	13/11	CI
Transcript : Acer Therapeutics Inc. - Shareholder/Analyst Call	08/11
Acer Therapeutics Inc.(OTCPK:ACER) dropped from NASDAQ Composite Index	08/11	CI
North American Morning Briefing : Inflation -2-	06/23/06	DJ
HC Wainwright Downgrades Acer Therapeutics to Neutral From Buy	05/23/05	MT
North American Morning Briefing : Chinese Data -2-	05/23/05	DJ
Top Midday Decliners	02/23/02	MT
Roth MKM Downgrades Acer Therapeutics to Neutral From Buy, Price Target is $1.50	01/23/01	MT
Sector Update: Health Care Stocks Lower in Late Afternoon Trading	01/23/01	MT
Sector Update: Health Care	01/23/01	MT
Top Midday Gainers	31/23/31	MT
Zevra Therapeutics to Acquire Acer Therapeutics in Merger Deal	31/23/31	MT
Transcript : Acer Therapeutics Inc., Zevra Therapeutics, Inc. - M&A Call	31/23/31
Relief Therapeutics Sells License for Urea Cycle Disorder Drug to Acer Therapeutics	31/23/31	MT
Zevra Therapeutics, Inc. acquired Acer Therapeutics Inc. for $91.7 million.	31/23/31	CI
Relief Therapeutics Holding AG Announces New Exclusive Definitive License Agreement for OLPRUVA(TM) (ACER-001) with Acer Therapeutics	31/23/31	CI
North American Morning Briefing : China Trouble Hits Sentiment	18/23/18	DJ
Acer Therapeutics Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2023	15/23/15	CI
Acer Therapeutics Inc.(NasdaqCM:ACER) dropped from Russell 3000E Growth Index	23/23/23	CI

Chart Acer Therapeutics Inc.

Duration

Period

More charts

Company Profile

Acer Therapeutics Inc. is a pharmaceutical company, which is focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. The Companyâs product pipeline includes OLPRUVA (sodium phenylbutyrate), ACER-801 (osanetant) and EDSIVO (celiprolol). OLPRUVA (sodium phenylbutyrate) for oral suspension is a formulation of sodium phenylbutyrate powder, for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD). Its ACER-801 (osanetant) is an investigational non-hormonal, neurokinin 3 receptor (NK3R) antagonist for the treatment of asomotor symptoms (VMS), post-traumatic stress disorder (PTSD), and prostate cancer. Its EDSIVO (celiprolol) is a selective adrenergic modulator for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	12TCr
REGENERON PHARMACEUTICALS, INC.	+12.15%	11TCr
BIONTECH SE	-8.14%	2.34TCr
ARGENX SE	-1.69%	2.18TCr
GENMAB A/S	-10.60%	1.81TCr
WUXI APPTEC CO., LTD.	-41.25%	1.67TCr
BEIGENE, LTD.	-15.33%	1.6TCr
NEUROCRINE BIOSCIENCES, INC.	+5.80%	1.4TCr
SAREPTA THERAPEUTICS, INC.	+28.03%	1.17TCr

Bio Therapeutic Drugs